HTTP/1.0 200 OK Content-Type: text/html Spain to Test Cannabis As Aid for Patients 
Pubdate: Sun, 06 Feb 2005
Source: Observer, The (UK)
Copyright: 2005 The Observer
Contact:  http://www.observer.co.uk/
Details: http://www.mapinc.org/media/315
Authors: Ben Sills, in Madrid and Jo Revill, The Observer
Bookmark: http://www.mapinc.org/mmj.htm (Cannabis - Medicinal)
Bookmark: http://www.mapinc.org/find?232 (Chronic Pain)
Bookmark: http://www.mapinc.org/topics/Sativex
Bookmark: http://www.mapinc.org/find?131 (Heroin Maintenance)

SPAIN TO TEST CANNABIS AS AID FOR PATIENTS

Spain's socialist government has given the go-ahead for the most 
wide-ranging trial of therapeutic cannabis ever conducted, putting the 
country at the forefront of drug policy.

Four hospitals, 60 pharmacies and up to 1,500 patients in Catalunya will 
take part in a year-long pilot programme sponsored by the regional 
government to establish the drug's effectiveness in treating a range of 
conditions.

'Experts agree cannabis has interesting therapeutic possibilities,' said 
Rafael Manzanera, Catalunya's director of health resources. 'We want to 
evaluate its efficacy across different groups of patients. That has never 
been done before.'

Patients will be prescribed cannabis capsules for four conditions: multiple 
sclerosis (MS); the side effects of chemotherapy; lack of appetite among 
Aids sufferers; and pain not eased by existing therapies.

The move follows decisions around the world to overcome anti-drug 
sentiments and carry out more studies into cannabis, many years after 
research first showed it could relieve pain. In the next few weeks Canada 
is expected to approve the use of Sativex, which delivers cannabis 
derivatives into the bloodstream via a mouth spray. It is the world's first 
prescription drug made from marijuana, and is manufactured by GW 
Pharmaceuticals.

There is growing frustration in the UK among people with chronic pain, such 
as MS sufferers, that nothing similar has been allowed here. The Medicines 
and Healthcare Products Regulatory Agency has asked GW for a confirmatory 
study of the product, although it does not dispute its safety or efficacy.

In most European countries, including Spain, cannabis remains illegal, 
although authorities often turn a blind eye to those using it for 
therapeutic purposes. The plan for a trial using a marijuana compound was 
initially blocked by Spain's conservative government but won support after 
Jose Luis Rodriguez Zapatero's socialists came to power last March.

Zapatero has set an unapologetically left-wing social agenda since taking 
office. He has angered Spain's conservative establishment with bold reforms 
on gay marriage, social housing and religious education, and his drugs 
policy is expected soon to include a programme of heroin prescription for 
long-term addicts.

Therapeutic cannabis use is widespread in Spain, but users have to rely on 
informal networks for support and information about the drug. And with no 
controlled source, supplies can vary considerably in strength.

'The majority of the people we spoke to said using cannabis had improved 
their quality of life,' said Rafael Borras, a committee member at the 
College of Pharmacists. 'But there was a real lack of information. So we 
proposed this pilot.'

Montse Domenech, of the Association of Breast Cancer Patients in Barcelona, 
says her group gets three or four calls a day from women all over Spain 
looking for advice about cannabis. But while its use is widespread among 
her members, it remains frowned upon. 'We're older women and we have our 
hang-ups,' she said. 'When I started I had my oncologist's support but I 
didn't tell my husband.'

She says most oncologists in Barcelona will give patients the go-ahead to 
try cannabis, even if they won't admit it publicly. 'We might as well 
provide support and control, since people are going to take it anyway.'

British patients could be included in the Spanish programme if they 
registered at one of the participating hospitals, but they wouldn't receive 
NHS funding.

'The prescription will be tightly controlled,' said Manzanera. 'But if 
patients from outside Spain meet our criteria, they will be included.'